Only the U.S., China, Germany, India and Japan had larger 2024 gross domestic products than Nvidia’s market value, according ...

Although anti-calcitonin gene-related peptides are safe and efficacious for adolescents with chronic migraine, access to treatment is often subject to extended insurance authorization delays, ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly (LLY) closed at $786.92 in the latest trading session, marking a +1.19% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.61% for the day. On the other ...

At last year’s inaugural “Famous Hoosiers” program Richard Gunderman made a moving and very well received presentation about ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Eli Lilly (NYSE:LLY) announced a significant global licensing and research collaboration with Juvena Therapeutics to explore AI-driven drug candidates for muscle health. This innovative move ...

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years. 2.

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and more than $650 million in milestones. The partners will use Juvena’s ...

Eli Lilly (LLY) is reportedly nearing a deal to acquire gene editing startup Verve Therapeutics (VERV) for up to $1.3 billion, the Financial Times reported.